Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
9.180
+0.620 (+7.24%)
Official Closing Price
Updated: 8:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Cybin Inc. Provides Corporate Update
June 08, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Changes in Scientific Management Team
June 05, 2023
Via
Investor Brand Network
Cybin Announces Scientific Management Transition Following Achievement of Final Adelia Milestones
June 05, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at Jefferies Healthcare Conference
June 01, 2023
Via
Investor Brand Network
Cybin to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Common Stock Purchase Agreement Totaling $30M
May 31, 2023
Via
Investor Brand Network
Topics
Derivatives
Exposures
Derivatives
Cybin Announces US$30M Common Stock Purchase Agreement from Lincoln Park Capital Fund
May 30, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial
May 24, 2023
Via
Investor Brand Network
Cybin Initiates First-in-Human Dosing of CYB004 in Phase 1 Clinical Trial
May 24, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial
May 09, 2023
Via
Investor Brand Network
Cybin Announces Last Subject Dosed in Part B of its Phase 1 CYB004-E Trial
May 09, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate at Upcoming Milken Institute Global Conference
April 28, 2023
Via
Investor Brand Network
Cybin to Participate at the 26th Annual Milken Institute Global Conference
April 28, 2023
From
Cybin Inc.
Via
Business Wire
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches EMBARK OA, a Cost-Free Facilitator Training Program for Psychedelic Therapy
April 12, 2023
Via
Investor Brand Network
Cybin Announces EMBARK Open Access, the First Free Online Course Providing Facilitator Training for Psychedelic Therapy
April 12, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate at Oppenheimer 33rd Annual Health Care Conference
March 08, 2023
Via
Investor Brand Network
Cybin to Participate in the Oppenheimer 33rd Annual Healthcare Conference
March 08, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Joins Chopra Foundation Founder, Other Experts in Psychedelics Discussions
March 03, 2023
Via
Investor Brand Network
Cybin and The Chopra Foundation to Participate in Featured Session at Upcoming 2023 South by Southwest® Conference
March 02, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Progress Updates on Two Clinical Development Programs
February 28, 2023
Via
Investor Brand Network
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
February 28, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Plan to Streamline Efforts, Maximize Efficiency, Focus on Clinical Trials
February 23, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Streamlined Clinical Alignment
February 22, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q3 Financial Report, Corporate Highlights
February 14, 2023
Via
Investor Brand Network
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
February 14, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives Approval for First-in-Human Dosing of Proprietary DMT Molecule
February 01, 2023
Via
Investor Brand Network
Cybin Announces Approval of First-in-Human Dosing of its Proprietary DMT Molecule CYB004
February 01, 2023
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Virtual R&D Day
January 26, 2023
Via
Investor Brand Network
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
Cybin to Host Virtual R&D Day on February 28, 2023
January 26, 2023
From
Cybin Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
17
18
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.